Back To Results

Education *CME

August 20, 2020

Journal Club Premieres with Therapeutic Pipeline (CME)

Episode 88

A discussion with dermatologists Dr. Mark Lebwohl and Dr. Andrew Blauvelt.

Join us for our new Psound Bytes Journal Club series discussing noteworthy publications in psoriatic disease. In this first episode, we discuss three recent trial results for therapeutics in the pipeline with dermatologists Dr. Mark Lebwohl, Professor and Chairman Dept. of Dermatology, Icahn School of Medicine, Mt Sinai Health System in New York, and Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR.

For disclosures and to claim CME credits, visit this page.

Publications:

Roflumilast

TyK2 Inhibitor

Bimekizumab

Share
Related Items

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.